MCID: BLD008
MIFTS: 34

Bladder Carcinoma in Situ

Categories: Blood diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Bladder Carcinoma in Situ

MalaCards integrated aliases for Bladder Carcinoma in Situ:

Name: Bladder Carcinoma in Situ 12 15
Flat Cis of the Urinary Bladder 12
Carcinoma in Situ of Bladder 12
Bladder Ca in Situ 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9053
ICD9CM 35 233.7
NCIt 50 C3644
SNOMED-CT 68 92546004
ICD10 33 D09.0
UMLS 72 C0154091

Summaries for Bladder Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the bladder.

MalaCards based summary : Bladder Carcinoma in Situ, also known as flat cis of the urinary bladder, is related to transitional cell carcinoma and papilloma. An important gene associated with Bladder Carcinoma in Situ is CCND3 (Cyclin D3), and among its related pathways/superpathways are Viral carcinogenesis and DNA Damage Response. The drugs Durvalumab and BCG vaccine have been mentioned in the context of this disorder. Affiliated tissues include prostate and bladder.

Related Diseases for Bladder Carcinoma in Situ

Diseases in the Bladder Cancer family:

Bladder Carcinoma in Situ

Diseases related to Bladder Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 30.3 UPK2 TP53 KRT7 CDKN2A
2 papilloma 30.0 TP53 KRT7 CDKN2A
3 bladder cancer 29.7 UPK2 TP53 MIR221 KRT19 CDKN2A
4 gall bladder carcinoma in situ 12.5
5 in situ carcinoma 10.7
6 splenic diffuse red pulp small b-cell lymphoma 10.6 TP53 CCND3
7 retroperitoneum carcinoma 10.6 UPK2 CDKN2A
8 keratinizing squamous cell carcinoma 10.5 TP53 CDKN2A
9 spitz nevus 10.5 TP53 CDKN2A
10 bile duct adenoma 10.5 KRT7 CDKN2A
11 inverted transitional papilloma 10.5 KRT7 CDKN2A
12 vulva squamous cell carcinoma 10.5 TP53 CDKN2A
13 bartholin's gland disease 10.5 TP53 CDKN2A
14 gastric diffuse adenocarcinoma 10.5 UPK2 KRT7
15 thyroid lymphoma 10.5 TP53 CDKN2A
16 anal squamous cell carcinoma 10.5 TP53 CDKN2A
17 gastric adenosquamous carcinoma 10.5 TP53 CDKN2A
18 endocervical carcinoma 10.5 KRT7 CDKN2A
19 megaesophagus 10.5 TP53 CDKN2A
20 adenoid basal cell carcinoma 10.5 KRT7 CDKN2A
21 malignant spiradenoma 10.5 TP53 KRT7
22 spiradenoma 10.5 TP53 KRT7
23 vulval paget's disease 10.5 KRT7 CDKN2A
24 oral leukoplakia 10.5 TP53 CDKN2A
25 uterus carcinoma in situ 10.5 TP53 CDKN2A
26 vulvar intraepithelial neoplasia 10.5 TP53 KRT7
27 cervix uteri carcinoma in situ 10.5 TP53 CDKN2A
28 nasal cavity cancer 10.5 KRT7 CDKN2A
29 anogenital venereal wart 10.5 TP53 CDKN2A
30 meningeal melanomatosis 10.5 TP53 CDKN2A
31 vulva adenocarcinoma 10.4 KRT7 CDKN2A
32 anal canal carcinoma 10.4 KRT7 CDKN2A
33 suppressor of tumorigenicity 3 10.4 TP53 CDKN2A
34 papillary serous adenocarcinoma 10.4 TP53 KRT7
35 dedifferentiated liposarcoma 10.4 TP53 CDKN2A
36 female reproductive endometrioid cancer 10.4 TP53 KRT7
37 well-differentiated liposarcoma 10.4 KRT7 CDKN2A
38 mucinous bronchioloalveolar adenocarcinoma 10.4 KRT7 CDKN2A
39 penile disease 10.4 TP53 CDKN2A
40 prostate squamous cell carcinoma 10.4 TP53 KRT7
41 cervix small cell carcinoma 10.4 TP53 CDKN2A
42 nasal cavity squamous cell carcinoma 10.4 KRT7 CDKN2A
43 pleomorphic carcinoma 10.4 TP53 KRT7
44 verrucous carcinoma 10.4 TP53 CDKN2A
45 eccrine sweat gland neoplasm 10.4 TP53 KRT7
46 intrahepatic bile duct adenoma 10.3 KRT7 KRT19
47 proliferating trichilemmal cyst 10.3 KRT7 KRT19
48 anal gland adenocarcinoma 10.3 KRT7 KRT19
49 tongue disease 10.3 TP53 CDKN2A
50 cervical adenosquamous carcinoma 10.3 KRT7 CDKN2A

Graphical network of the top 20 diseases related to Bladder Carcinoma in Situ:



Diseases related to Bladder Carcinoma in Situ

Symptoms & Phenotypes for Bladder Carcinoma in Situ

Drugs & Therapeutics for Bladder Carcinoma in Situ

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Bacillus calmette-guerin substrain connaught live antigen Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). DB10804

Drugs for Bladder Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Durvalumab Approved, Investigational Phase 2 1428935-60-7
2
BCG vaccine Investigational Phase 2
3 Adjuvants, Immunologic Phase 2
4 Immunologic Factors Phase 2
5 Antineoplastic Agents, Immunological Phase 2
6 Antibodies Phase 2
7 Immunoglobulins Phase 2
8 Antibodies, Monoclonal Phase 2
9 Vaccines Phase 2
10
Altretamine Approved Phase 1 645-05-6 2123
11
Valrubicin Approved 56124-62-0 41744

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder Recruiting NCT02901548 Phase 2 Durvalumab
2 A First-in-Human Phase I Study of Intravesical sEphB4-HSA in Patients With "BCG-Unresponsive" Bladder Carcinoma In Situ (CIS), Completely Resected High Grade Ta/T1, to Establish the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) Not yet recruiting NCT03552796 Phase 1
3 A Retrospective Analysis to Evaluate the Effectiveness, Safety and Tolerability of Intravesical Valrubicin for the Treatment of Bladder Carcinoma in Situ in Clinical Practice Completed NCT01304173

Search NIH Clinical Center for Bladder Carcinoma in Situ

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Bacillus calmette-guerin substrain connaught live antigen

Genetic Tests for Bladder Carcinoma in Situ

Anatomical Context for Bladder Carcinoma in Situ

MalaCards organs/tissues related to Bladder Carcinoma in Situ:

41
Prostate

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Carcinoma in Situ:

19
Bladder

Publications for Bladder Carcinoma in Situ

Articles related to Bladder Carcinoma in Situ:

(show top 50) (show all 98)
# Title Authors PMID Year
1
Tuberculous Orchitis Following Intravesical Bacille Calmette-Guérin (BCG) Therapy. 38
30062077 2018
2
Probe-Based Confocal Laser Endomicroscopy Using Acrinol as a Novel Dye Can Be Used to Observe Cancer Nuclei of Bladder Carcinoma In Situ. 38
29503871 2018
3
Educational Case: Bladder Carcinoma In Situ. 38
30140732 2018
4
Safe and effective administration of BCG for bladder carcinoma in situ after umbilical cord blood stem cell transplantation. 38
28796929 2017
5
5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer. 38
28191719 2017
6
Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. 38
27664578 2017
7
Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases. 38
28994883 2016
8
Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin. 38
26777259 2016
9
Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy? 38
27072170 2016
10
Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. 38
25466937 2015
11
Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ? 38
25660358 2015
12
Complication of treatment of carcinoma in situ of the bladder with photodynamic targeted cystodiathermy. 38
25245722 2014
13
Cancer identified incidentally in the prostate following radical cystoprostatectomy: an Australian study. 38
23216652 2014
14
Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra. 38
24144432 2014
15
Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided? 38
23551700 2014
16
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. 38
22575238 2013
17
Bladder carcinoma in situ (CIS) in Australia: a rising incidence for an under-reported malignancy. 38
23573811 2013
18
p16(INK4a) /Ki-67 dual labelling as a marker for the presence of high-grade cancer cells or disease progression in urinary cytopathology. 38
23003335 2013
19
Fever of unknown origin and pancytopenia caused by culture-proven delayed onset disseminated bacillus Calmette-Guerin (BCG) infection after intravesical instillation. 38
23576657 2013
20
A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. 38
23410519 2013
21
Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy. 38
23383616 2013
22
Penile tuberculosis following intravesical Bacille Calmette-Guérin immunotherapy. 38
23671370 2013
23
Carcinoma in situ of urinary bladder: incidence, treatment and clinical outcomes during ten-year follow-up. 38
23115943 2012
24
[Tubercular prostatic abscess following intravesical Bacillus Calmette-Guerin therapy]. 38
22495047 2012
25
Early detection of carcinoma in situ of the bladder: a comparative study of white light cystoscopy, narrow band imaging, 5-ALA fluorescence cystoscopy and 3-dimensional optical coherence tomography. 38
22245332 2012
26
Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ. 38
21566413 2011
27
Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. 38
21167566 2011
28
The clinical impact of the classification of carcinoma in situ on tumor recurrence and their clinical course in patients with bladder tumor. 38
21169349 2011
29
Mycobacterium bovis spondylodiscitis after intravesical Bacillus Calmette-Guérin therapy. 38
22140647 2011
30
Cyclin D3 gene amplification in bladder carcinoma in situ. 38
20821231 2010
31
Enhancing detection of bladder carcinoma in situ by 3-dimensional optical coherence tomography. 38
20723922 2010
32
Clinical outcome of primary versus secondary bladder carcinoma in situ. 38
20620399 2010
33
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. 38
20546806 2010
34
Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder. 38
19957324 2010
35
A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancer. 38
21358881 2010
36
The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy. 38
18440839 2009
37
Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. 38
19237175 2009
38
Relaxation training and guided imagery for an elderly man with bladder cancer: a case report. 38
20671329 2009
39
Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. 38
18423745 2008
40
[BCG infection of the glans penis after intravesical BCG therapy]. 38
18598797 2008
41
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. 38
17689003 2008
42
Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. 38
19034342 2007
43
Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer. 38
17487406 2007
44
Enhanced formation of nitric oxide in bladder carcinoma in situ and in BCG treated bladder cancer. 38
16517187 2006
45
Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. 38
16890661 2006
46
A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. 38
16301114 2005
47
Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy. 38
16323989 2005
48
[Early diagnosis of bladder carcinoma]. 38
17877124 2005
49
The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. 38
15610101 2004
50
Mucinous adenocarcinoma of the renal pelvis associated with transitional cell carcinoma in the renal pelvis and the bladder. 38
15509208 2004

Variations for Bladder Carcinoma in Situ

Expression for Bladder Carcinoma in Situ

Search GEO for disease gene expression data for Bladder Carcinoma in Situ.

Pathways for Bladder Carcinoma in Situ

GO Terms for Bladder Carcinoma in Situ

Biological processes related to Bladder Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.02 MIR221 MIR199B MIR142 MIR139 MIR133A1
2 replicative senescence GO:0090399 8.96 TP53 CDKN2A

Sources for Bladder Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....